SWP
VTVT icon

Strategic Wealth Partners’s vTv Therapeutics VTVT Stock Holding History

Strategic Wealth Partners’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40 Hold
1
– – ﹤0.01% 1425
2025
Q4 		$40 Hold
1
– – ﹤0.01% 1418
2025
Q3 		$23 Hold
1
– – ﹤0.01% 1301
2025
Q2 		$15 Buy
+1
New +$18 ﹤0.01% 1137

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Strategic Wealth Partners's VTVT Position: Q1 2026 in Review

Strategic Wealth Partners held its vTv Therapeutics (VTVT) position steady in Q1 2026 at 1 share worth $40. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

Strategic Wealth Partners first reported a position in VTVT in Q2 2025 and has held it in 4 quarters since. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

  • Strategic Wealth Partners held 1 share of vTv Therapeutics worth $40 as of Q1 2026.
  • Strategic Wealth Partners left its vTv Therapeutics share count unchanged in Q1 2026.
  • vTv Therapeutics made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q1 2026, its #1425 holding.
  • Strategic Wealth Partners first reported a position in vTv Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on Strategic Wealth Partners's 13F filing for Q1 2026, filed 12 May 2026.